1435 related articles for article (PubMed ID: 29950407)
1. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
[TBL] [Abstract][Full Text] [Related]
2. Herpes Simplex Virus 1 Mutant with Point Mutations in
Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication.
Wang H; Davido DJ; Mostafa HH; Morrison LA
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632611
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.
Keadle TL; Morrison LA; Morris JL; Pepose JS; Stuart PM
J Virol; 2002 Apr; 76(8):3615-25. PubMed ID: 11907201
[TBL] [Abstract][Full Text] [Related]
5. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.
Geiss BJ; Smith TJ; Leib DA; Morrison LA
J Virol; 2000 Dec; 74(23):11137-44. PubMed ID: 11070010
[TBL] [Abstract][Full Text] [Related]
6. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
Morrison LA; Knipe DM
J Virol; 1994 Feb; 68(2):689-96. PubMed ID: 8289372
[TBL] [Abstract][Full Text] [Related]
7. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency.
Halford WP; Schaffer PA
J Virol; 2001 Apr; 75(7):3240-9. PubMed ID: 11238850
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1.
Morrison LA; Knipe DM
Virology; 1996 Jun; 220(2):402-13. PubMed ID: 8661391
[TBL] [Abstract][Full Text] [Related]
9. Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice.
Matundan H; Mott KR; Ghiasi H
J Virol; 2014 Jul; 88(14):8016-27. PubMed ID: 24807710
[TBL] [Abstract][Full Text] [Related]
10. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
Augustinova H; Hoeller D; Yao F
J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus virion host shutoff (vhs) activity alters periocular disease in mice.
Smith TJ; Ackland-Berglund CE; Leib DA
J Virol; 2000 Apr; 74(8):3598-604. PubMed ID: 10729135
[TBL] [Abstract][Full Text] [Related]
12. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
[TBL] [Abstract][Full Text] [Related]
14. Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo.
Halford WP; Schaffer PA
J Virol; 2000 Jul; 74(13):5957-67. PubMed ID: 10846077
[TBL] [Abstract][Full Text] [Related]
15. Mutations Inactivating Herpes Simplex Virus 1 MicroRNA miR-H2 Do Not Detectably Increase ICP0 Gene Expression in Infected Cultured Cells or Mouse Trigeminal Ganglia.
Pan D; Pesola JM; Li G; McCarron S; Coen DM
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847363
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.
van Lint AL; Torres-Lopez E; Knipe DM
Virology; 2007 Nov; 368(2):227-31. PubMed ID: 17915278
[TBL] [Abstract][Full Text] [Related]
17. An M2 Rather than a T
Lee DH; Ghiasi H
J Virol; 2018 May; 92(10):. PubMed ID: 29491152
[TBL] [Abstract][Full Text] [Related]
18. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
[TBL] [Abstract][Full Text] [Related]
19. A non-consensus branch point plays an important role in determining the stability of the 2-kb LAT intron during acute and latent infections of herpes simplex virus type-1.
Mukerjee R; Kang W; Suri V; Fraser NW
Virology; 2004 Jul; 324(2):340-9. PubMed ID: 15207620
[TBL] [Abstract][Full Text] [Related]
20. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
